Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

This phase I/II trial characterized the tolerability, safety, and antitumor activities of unecritinib, a novel derivative of crizotinib and a multi-tyrosine kinase inhibitor targeting ROS1, ALK, and c-MET, in advanced tumors and ROS1 inhibitor-naive advanced or metastatic non-small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Pan, Hongming, Wu, Lin, Yao, Yu, He, Jianxing, Wang, Yan, Wang, Xiuwen, Fang, Yong, Zhou, Zhen, Wang, Xicheng, Cai, Xiuyu, Yu, Yan, Ma, Zhiyong, Min, Xuhong, Yang, Zhixiong, Cao, Lejie, Yang, Huaping, Shu, Yongqian, Zhuang, Wu, Cang, Shundong, Fang, Jian, Li, Kai, Yu, Zhuang, Cui, Jiuwei, Zhang, Yang, Li, Man, Wen, Xinxuan, Zhang, Jie, Li, Weidong, Shi, Jianhua, Xu, Xingxiang, Zhong, Diansheng, Wang, Tao, Zhu, Jiajia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310851/
https://www.ncbi.nlm.nih.gov/pubmed/37385995
http://dx.doi.org/10.1038/s41392-023-01454-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310851/
https://www.ncbi.nlm.nih.gov/pubmed/37385995
http://dx.doi.org/10.1038/s41392-023-01454-z

Ejemplares similares